Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome.
Satoh
Noriko
N
Clinical Research Institute for Endocrine Metabolic Diseases, National Hospital Organization, Kyoto Medical Center, 1-1 Fukakusa Mukaihata-cho, Fushimi-ku, Kyoto 612-8555, Japan. nsato@kyotolan.hosp.go.jp
Shimatsu
Akira
A
Kotani
Kazuhiko
K
Sakane
Naoki
N
Yamada
Kazunori
K
Suganami
Takayoshi
T
Kuzuya
Hideshi
H
Ogawa
Yoshihiro
Y
D016718:Arachidonic Acid / Q000097:blood; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000187:drug effects / Q000378:metabolism*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015118:Eicosapentaenoic Acid / Q000097:blood / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000097:blood; D008074:Lipoproteins / Q000097:blood* / Q000187:drug effects; D008077:Lipoproteins, LDL / Q000097:blood* / Q000187:drug effects; D024821:Metabolic Syndrome / Q000097:blood*; D009765:Obesity / Q000097:blood*
D016718:Arachidonic Acid; D002097:C-Reactive Protein; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015118:Eicosapentaenoic Acid; D006442:Glycated Hemoglobin; D007328:Insulin; D008074:Lipoproteins; D008077:Lipoproteins, LDL